A randomized multicenter, open label, controlled and non-comparative phase II study of anti-PDL1 ATEZOLIZUMAB (MPDL3280A) or chemotherapy as second-line therapy in patients with small cell lung cancer (SCLC)
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Topotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 25 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Jun 2020.
- 25 Feb 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2019.
- 18 Jan 2019 Status changed from active, no longer recruiting to completed.